Patterns of steroid utilization in COVID-19 patients (Q21-02)

Patterns of steroid utilization in COVID-19 patients (Q21-02)

Q21-02_CDM

Overview

Background

The National Institute of Health’s COVID-19 Treatment Guidelines state that dexamethasone should not be used in outpatients with mild to moderate COVID-19, or in hospitalized patients who do not require supplemental oxygen. Preliminary results from the United States Federal Drug Administration (FDA) indicate that corticiosteroids are administered in approximately 15% of outpatients with a COVID-19 diagnosis. In collaboration with the FDA and the European Medicines Agency (EMA), this study will describe the patterns of CS use in outpatients with COVID-19 from several Canadian provinces and evaluate the effects of this use on important adverse outcomes.

Aim

To describe the utilization patterns, clinical and demographic characteristics and outcomes among patients with a COVID-19 diagnosis who initiate oral or injectable CS therapy in an outpatient setting.

Manuscripts

Presentations

Project Team

Project Co-Lead
Robert W. Platt PhD
Project Co-Lead
Michael Paterson MSc
Project Manager
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Dan Chateau PhD
Manitoba
Site Investigator
Colin R. Dormuth ScD
British Columbia
Analyst
Fangyun Wu MSc
Ontario
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Sean Burnett MA, Econ
British Columbia